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Background & aims: Protein source, macronutrient composition and content of long chain-
polyunsaturated fatty acids (LC-PUFA) of infant formulae may inﬂuence infant growth. We aimed to
assess the effect of a modiﬁed infant formula on growth.
Methods: In a randomized, double-blind trial, 213 healthy term infants consumed isoenergetic study
formulae (intervention formula e IF, control formula e CF) from the ﬁrst month of life until the age of
120 days. IF (1.89 g protein/100 kcal) contained a-lactalbumin (ALAB) and LC-PUFA, while CF (2.30 g
protein/100 kcal) provided standard whey and no LC-PUFA. Anthropometry and dietary intake were
regularly assessed. A venous blood sample was obtained on day 120.
Results: Both formulae were well-accepted without signiﬁcant differences in health related observations.
Weight gain was not statistically different between formula groups (IF: 30.2  6.3 vs. CF: 28.3  6.5 g/day,
mean  SD, P ¼ 0.06). Length gain was higher in IF (0.11  0.02 vs. 0.10  0.02 cm/day, P ¼ 0.02). Energy
intake from formula was higher in CF at 90 and 120 days (IF: 509  117 and 528  123 vs. CF: 569  152
and 617  169 kcal/day, P < 0.01). Protein intake in CF was signiﬁcantly higher at each assessment.
Growth per energy intake was higher in IF compared to CF for weight (6.45  2.01 vs. 5.67  2.21 g/
100 kcal, P ¼ 0.02) and length (0.23  0.08 vs. 0.20  0.08 mm/100 kcal, P ¼ 0.04).
Conclusions: The modiﬁed infant formula with reduced protein content with added ALAB and LC-PUFA,
meets infant requirements of protein for adequate growth. The increased energetic efﬁciency of the new
infant formula might result from improved protein composition by added ALAB. Apparently minor dif-
ferences in composition can markedly affect energetic efﬁciency for growth.
The study was registered at ClinicalTrials.gov (NCT01094080).
 2014 The Authors. Published by Elsevier Ltd and European Society for Clinical Nutrition and
Metabolism. Open access under CC BY-NC-SA license.Munich Infant Milk Trial; BF,
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Infants should be fully breastfed for 6monthswhenever feasible.1
Infants beneﬁt frombreastfeedingnot only via immediate protection
against gastrointestinal and respiratory infections,2 but also via a
lower risk of obesity and diabetes in adult life.3,4 If full breastfeeding
is not possible, safe and suitable infant formulae should be fed.5
During the last decades, infant formulae have been improved for
example by the inclusion of long chain-polyunsaturated fatty acids
(LC-PUFA)6 and adaptation of content and source of protein.7,8
Protein intake of infants is lower with breast milk than with stan-
dard infant formulae9 because of a generally higher formula protein
content considering the lower nutritive value of cow’s milk caseinical Nutrition and Metabolism. Open access under CC BY-NC-SA license.
Table 1
Composition of study formulae and human milk.
Infant formula Human milka
Intervention Control
Whey:casein ratio 60:40 60:40 60:40
Energy (kcal/100 mL) 67 67 67  7.6
Protein (g/100 kcal) 1.89 2.2 e
Protein (g/100 mL) 1.3 1.5 1.2  0.2
Lipids (g/100 mL) 3.6 3.3 3.6  0.7
Carbohydrates (g/100 mL) 7.5 7.8 7.4  0.2
a Nommsen et al. 1991, Food and Nutrition Board 2001.52,53
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amino acid (AA) composition may require higher amounts of cow’s
milk protein to ensure adequate supply of essential AA,10 which puts
additional burden on the renal system because of the higher nitrogen
intake.11 According to the “early protein hypothesis”3 high protein
intake causes rapid early growth, which has been associated with an
increased riskof obesityandassociateddisorders in later life.12,13 Thus,
lower protein intake in infancy seems beneﬁcial for long term health.
Davis et al. 2008 investigated the use of an infant formula with
a-lactalbumin (ALAB).14 ALAB, the predominant whey fraction in
human milk, is the main source of tryptophan (Trp) of breastfed
infants and enables the reduction of protein content in infant
formulae, while ensuring sufﬁcient supply of Trp and all other
essential AA.15,16 The composition of milk consumed by infants
affects the energy efﬁciency for growth: Butte et al. 1990 compared
the energy efﬁciency of infants at the ages of 1 and 4 months and
found that breastfed infants had an 11% higher weight gain per
100 kcal (energetic efﬁciency) than formula fed infants.17
The inclusion of LC-PUFA into formula aimed to optimize the
neuronal development as LC-PUFA are quantitatively and qualita-
tively important components of nervous tissue and provided by
human milk.18 The LC-PUFAs, arachidonic acid and docosahexaenoic
acid, may enhance visual acuity and mental as well as psychomotor
development.19 Moreover, there might be interactions with growth
as arachidonic acid has been related to growth and LC-PUFA derived
prostaglandin may inﬂuence adipocyte differentiation.20,21
Since the modiﬁcation of protein source, macronutrient compo-
sitionandcontentof LC-PUFAof infant formulaemay inﬂuence infant
growthanddevelopment,modiﬁed formulamust be tested to ensure
they support adequate growth.22 In present study we compared
growth and blood biochemistry of infants fed a modiﬁed infant for-
mulawith reduced protein content and rich in ALAB aswell as added
LC-PUFA to a formulawith standard protein content andwithout LC-
PUFA, and a reference group of breastfed infants. The randomized
controlled trial aimed to assess the suitability of a reduced-protein,
ALAB and LC-PUFA containing formula focusing on growth veloc-
ities, adverse events, markers of fatty acids and protein status and
energetic efﬁciency in infants until the age of 120 days.
2. Subjects and methods
2.1. Power calculation and randomization
Based on previous ﬁndings a weight gain between birth and age
4 months of life of 30 g per day with a standard deviation of 6 g was
assumed for sample size estimation.23e26 The non-inferiority study
assumed a power of 85% and 2.5% risk of a-error to detect a dif-
ference of 0.5 standard deviations (one-sided test) as statistically
signiﬁcant required studying 70 infants per formula group.
Assuming a total loss to follow-up rate of up to 30% 100 infants
were enrolled into each formula arm.
Double blinded randomized allocation of infants to the study
formulae was stratiﬁed for gender and a block size of four was
applied. A random allocation sequence was generated by the study
sponsor. The blinded allocation was concealed for participants,
support staff and investigators until all laboratory and data analyses
had been performed.
2.2. Ethical considerations
The study was approved by the Clinical Center Serbia Ethical
Committee. Written informed consent was obtained from all par-
ents prior to study start after the experimental protocol had been
explained to them in detail.
The study was registered at ClinicalTrials.gov (NCT01094080).2.3. Study design
The BeMIM study (BelgradeeMunich Infant Milk Trial), a ran-
domized, double-blind, controlled study with parallel design, was
performed with two formula groups (intervention formulae IF and
control formula e CF) and a reference group of breastfed infants
(BF). Infants were recruited until the age of 28 days. Children of
mothers, who could not breastfeed their healthy newborn babies
for reasons not related to this study, or who decided e in spite of all
beneﬁts of breast milk e to start full formula-feeding within the
ﬁrst 28 days of life, were randomized double blinded into one of the
two formula groups. Formula infants (FF) were fully formula fed
until the age of 120 days. A reference group of breastfed infants was
recruited with intended duration of breastfeeding for at least 4
months. During the ﬁrst 28 days (Baseline) and at 30, 60, 90 and
120 days of life infants were examined and anthropometric mea-
sures were taken. During three days before each study examination
parents recorded the volume of consumed formula and completed
questionnaires on formula acceptance, consistency and color of
stool, occurrence of colic, ﬂatulence, regurgitation, and vomiting.
Weight was determined with a Seca 336 scale (Seca, Hamburg,
Germany) equipped with a measuring rod (Seca 232) for measuring
recumbent length, and head circumference was measured with a
tape (Seca 212). All measurements were performed in duplicate
and documented with an accuracy of 10 g for weight and 0.1 cm for
length and head circumference, respectively. The equipment was
regularly checked and calibrated to ensure accuracy of measure-
ments. These checks were done with a calibrated weight of 5 kg
every 4 weeks. There was never an aberration of more than 10 g.
Therefore, the scales were never reset.
2.4. Study population
From Jan 2010 toMay 2011, 505 infants were enrolled verbally at
thematernityward andwithﬂyers providing study information and
contact data of the principal investigator at the Institute for Gyne-
cology and Obstetrics of the Clinical Center of Serbia in Belgrade,
Serbia. Eligible infants had to be born apparently healthy from
singleton pregnancies after 37e41 weeks of gestation, with a birth
weight between the 3rd and 97th weight-for-age percentile ac-
cording to the EURO-Growth charts.27 Infants with malformations,
congenital heart defects, congenital vascular diseases, severe dis-
eases of gastrointestinal tract, kidney, liver, central nervous system,
or metabolic disease were excluded from study participation.
2.5. Study diets
Study formulae were provided free of charge to families by HiPP
GmbH & Co. Vertrieb KG (Pfaffenhofen, Germany) in 600 g cartoons
and labeled by random numbers. The products were packed in
identical white boxes and labeled with the same product name. IF
complied with the EU-directive of 200628 and CF with the corre-
sponding 1999 EU-directive.29 The formulas had identical whey/
M. Fleddermann et al. / Clinical Nutrition 33 (2014) 588e595590casein ratios of 60/40 and energy contents of 67 kcal/100 mL, but
differed in protein, fat and carbohydrate content (Table 1). IF had a
protein content of 1.89 g/100 kcal and a fat content of 5.3 g/100 kcal,
while CF contained 2.20 g/100 kcal and 4.9 g/100 kcal, respectively.
IF was rich in ALAB and supplemented with free L-phenylalanine
and L-tryptophan to meet required contents (Table 1, supplemental
data).28 Egg and ﬁsh oils providing arachidonic acid and docosa-
hexaenoic acid (each 10.7 mg/100 kcal) were added to IF (Table 2,
supplemental data).
2.6. Laboratory procedures
At 120 days of age venous blood samples was drawn >2 h after
the last feeding. Plasma urea, albumin, glucose and creatinine were
analyzed at the Clinical Center of Serbia. Plasma aliquots were
stored at 80 C and transported on dry ice to the Dr. von Hauner
Children’s Hospital (Munich, Germany) for the analyses of plasma
AA and glycerophospholipid fatty acids.
Quantitative AA analysis was performed by LC-MS/MS.30 The
samples were deproteinized by methanolic HCl and chemically
derivatized with butanolic HCl. Amino acid butyl esters were sepa-
rated on a XBridge C18 column (Waters, Eschborn, Germany) by ion-
pair reversed phase chromatography (HPLC 1100 SL, Agilent, Wald-
bronn, Germany) and quantiﬁed by triple quadrupole mass spec-
trometry (SciexAPI2000,AppliedBiosystems,Darmstadt,Germany).
Glycerophospholipid fatty acids were determined according to
Glaser et al. (2010a) with the use of gas chromatography with ﬂame
ionization detection (Agilent 7890A, Agilent Technologies, Mül-
heim an der Ruhr, Germany).31 Derivatization of fatty acids with
sodium methoxide was followed by separation of fatty acid methyl
esters by gas chromatography using a BPX70 (25 m*0.22 mm,
Phenomenex, Aschaffenburg, Germany) column.
2.7. Calculations
The anthropometric gain (weight, length and head circumfer-
ence) between 30 and 120 days of age was calculated. For calcu-
lation of the anthropometric gain per day, the results were divided
by the exact number of days between both visits of each subject.
The results were presented as weight: g/d, length: cm/d and head:
cm/d and were available for all subjects.
The daily energy and protein intake was calculated as the
average intake at 30, 60, 90 and 120 days of age and was available of
all four time points for 79 IF and 80 CF infants.
The energetic efﬁciency was calculated as ratio of the anthropo-
metric gain (weight and length) from 30 to 120 days of age to the
averageenergyorprotein intakeperdayduring thestudy.Themonthly
energetic efﬁciency was calculated from the anthropometric gain
duringonemonthof life and theenergyandprotein intakeassedat the
endof thismonth. Theenergetic efﬁciency is expressedasweightgain/
100 kcal or /g protein or as length gain/100 kcal or /g protein.
The SD scores (z scores) were calculated by using the anthro-
pometric results relative to the growth standards of the WHO for
breastfed children.26
2.8. Data management and statistical analysis
Data were collected in a MS Access database and statistical an-
alyses were performed with Stata/MP 11.0 (StataCorp LP, College
Station, TX, USA). Results are presented as mean  SD or medians
and interquartile ranges (IQR, 25th and 75th percentile). Pearson
chi-square test was used for statistical comparison of categorical
data, t-test for normally distributed continuous variables and
KruskaleWallis test for non-normally distributed continuousvariables. P-values below 0.05 were considered as statistically
signiﬁcant.
The weight gain (g/d) between 30 and 120 days of life was used
as primary outcome and was calculated by t-test. For comparison of
primary outcome between both formula groups and BF group po-
tential confounder (sex, maternal educational level, smoking dur-
ing pregnancy) were considered.
The primary (weight gain) and secondary (length and head
circumference gain) outcomes were analyzed for intention-to-treat
(ITT) and per-protocol (PP) populations. In the ITT analysis, all
subjects were considered that received study formula. In the PP
analysis, only data from subjects complying with the predeﬁned
conditions, no intake of other formula than study formula, a
maximum of 50 mL tea intake per day (mean over each 3-day-
protocol) and less than 3 spoons complementary food per week.
3. Results
A total of 505 infants were recruited (Fig. 1) including 213 FF in-
fants whowere randomly allocated to one of the study formulae. Of
this group 207 infants ﬁnally received study formula from 19  8
days of life onward (no signiﬁcant difference between groups).
During the intervention period forty infants dropped out of the
study (19.3%)becauseof parental refusal (n¼34),medication/illness
(n¼ 4) or loss of contact (n¼ 2). Three of the 167 infants completing
the studywere excluded fromthe analyses because not-fulﬁlling the
inclusion criteria (n ¼ 2) or because of implausible values (n ¼ 1).
Gender ratio, birth order, maternal age and education, smoking,
gestational age,mode of delivery, and anthropometry at birth and at
study entry were not signiﬁcantly different between the random-
ized formula groups (Table 3, supplemental data).
From the 185 BF infants 93 infants were lost to follow-up (50%)
because of parental refusal (n ¼ 76), medication/illness (n ¼ 3) and
loss of contact (n¼ 14). Baseline characteristics were comparable to
the FF infants, with the exception of mothers educational level and
rate of spontaneous deliveries, which were signiﬁcantly higher for
BF infants than for FF infants (P¼ 0.002 and P¼ 0.001, respectively).
3.1. Adverse events
Both formulae were well-accepted and no differences were re-
ported for acceptance as well as consistency and color of stool, colic,
ﬂatulence, regurgitation and vomiting. The total number of adverse
events (adverse event plus serious adverse event) was 21 in 88 IF
infants, 41 in 92 CF infants and 45 in 185 BF infants (Table 4,
supplemental data). Thus, a signiﬁcantly higher rate in adverse
events was observed in CF infants compared to IF (P¼ 0.003) and BF
infants (P ¼ 0.001), while IF and BF infants did not differ. The types
of adverse events were similarly distributed between formula
groups (49% respiratory tract infections, 24% skin infection/-
eczema, 10% gastrointestinal problems, 4% urinary tract in-
fections, and 13% others). The number of serious adverse events
was 12 in the formula groups (IF ¼ 9, CF ¼ 3) and 4 in the reference
group, with one serious adverse event in each formula group
considered a potentially association to the study formula (IF:
Vomiting, blood in stool, reﬂux and CF: Vomiting, blood in stool).
3.2. Growth
There were no differences between both formula groups for
weight gain from 30 to 120 days of age (Table 2, ITT population).
Length gain expressed as cm per day was signiﬁcantly higher in IF
(0.11  0.02 cm/day) compared to CF infants (0.10  0.02 cm/day,
P ¼ 0.02). In BF infants weight and length gains were signiﬁcantly
lower than in IF infants (Table 2). No signiﬁcant differences were
Fig. 1. Numbers of participants for randomization, allocation, follow-up and analysis.
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IF and CF; 0.05  0.02 cm/day for BF infants). Determined possible
confounders sex, smoking during pregnancy, mother’s age, ﬁrst
pregnancy and gestational age were not different between groups.
Additionally, we adjusted for weight or length at 30 days of age
to account for the fact that more extreme values tend to have lower
or higher gains, respectively. The adjusted estimated daily weight
gain for weight from 30 days to 120 days of age was found to be
1.94 g/d (95% CI: 0.04, 39.2; P ¼ 0.055) greater in IF group than in
CF group. The adjusted estimated daily length gain for length from
30 days to 120 days of age was found to be 0.05 mm/d (95% CI:
0.0006, 0.10; P ¼ 0.047) greater in IF group than in CF group.
Analyzing PP subjects, weight tended to be higher in IF
compared to CF (not signiﬁcant, Table 5, supplemental data). Mean
weight and length gains of IF infants were greater than of BF infants
(both P ¼ 0.01).
Results of z-scores are depicted in Fig. 1, supplemental data.3.3. Nutrient intake
The intake of study formula was similar between the groups at
30 and 60 days of age, but signiﬁcantly higher in CF infants at 90
and 120 days of age by average 90 and 140 mL, respectively. EnergyTable 2
Weight, length and head circumference gain in infants of the intention-to-treat
population.






No. of infants 82 82 92
Weight gain (g/d) 30.2  6.3a 28.3  6.5 26.7  6.4a
Length gain (cm/d) 0.11  0.02a,b 0.10  0.02a 0.10  0.02b
Head circ. gain (cm/d) 0.05  0.01 0.05  0.01 0.05  0.02
Data are presented as mean  SD. Identical letters indicating signiﬁcant differences
between groups (P < 0.05, Student’s t-test).and protein intakes determined from the 3 day protocols are
summarized in Fig. 2. Energy intake in IF and CF infants was
identical at 30 and 60 days of age, but at ages 90 and 120 days
higher energy intakes were observed for CF infants (569  152 vs.
509  117 kcal/d, P ¼ 0.005 and 617  169 vs. 528  123 kcal/d,
P < 0.001, respectively). The protein intake was signiﬁcantly higher
in CF infants than in IF infants (Fig. 2).
The intake of other foods than study formula was generally low.
There were no signiﬁcant differences between the intake of water,
tea, other formula than study formula, breastfeeding and comple-
mentary feeding between the formula groups during the whole
study period.
In the PP population, the same differences in volume, energy
and protein intake of IF and CF infants were found as in the ITT
population. Neither intake of liquid nor breastfeeding was different
between IF and CF infants (data not shown).
3.4. Growth in relation to intake
Weight and length gain from 30 to 120 days of age were related
to the average energy intake during the study as a marker for en-
ergetic efﬁciency of the formulae (Fig. 3). Weight gain per 100 kcal
was signiﬁcantly higher in IF infants (6.45  2.01 g/100 kcal) than
CF infants (5.67  2.21 g/100 kcal, P ¼ 0.02). A corresponding dif-
ference was observed for length gain per 100 kcal (IF
0.23  0.08 mm/100 kcal and CF 0.20  0.08 mm/100 kcal,
P ¼ 0.04). The energetic efﬁciency during the ﬁrst (birth to 30 days
of age) and second (30e60 days of age) month of life in IF and CF
infants was identical, but tended to be higher in IF during the third
month (60e90 days of age). During the fourth month (90e120 days
of age), the energetic efﬁciency of IF was signiﬁcantly higher than in
CF for weight 5.16  2.96 vs. 4.12  1.64 g/100 kcal and length
0.24  0.23 vs. 0.18  0.11 mm/100 kcal.
Weight gain by protein intake was signiﬁcantly higher in IF
(3.33  1.04 g/g protein) than in CF infants (2.53  0.99 g/g protein,
P < 0.001).
Fig. 2. Mean (SD) daily energy and protein intake at 30, 60, 90 and 120 day of age in intervention and control group of the intention-to-treat population. **P < 0.01, ***P < 0.001.
Signiﬁcantly different between groups (Student’s t-test).
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There were no signiﬁcant differences between the formula
groups for albumin, urea and creatinine. Compared with the BF
group, urea and creatinine were higher and glucose was lower in
both formula groups (Table 6, supplemental data). All analyzed AA
and fatty acid concentrations were within the normal ranges for
healthy infants or small children.14,32
Infants receiving IF formula showed a signiﬁcantly higher
plasma total fatty acid concentration of 1225 mg/L (interquartile
range: 1108, 1318) than CF infants (1071 mg/L: 988, 1202;
P < 0.001). Arachidonic acid (8.24 vs. 7.02%, P < 0.001) and doco-
sahexaenoic acid (4.51 vs. 1.48%, P < 0.001) percentages were
higher in IF infants (Table 7, supplemental data). The arachidonic
acid level was signiﬁcantly higher in BF infants compared to both
formula groups, while the docosahexaenoic acid level was highest
in IF infants, followed by breastfed infants and CF (all group dif-
ferences P < 0.01).
The concentrations of 14 AA were signiﬁcantly different be-
tween groups (Table 8, supplemental data). The total AA concen-
tration were 2907 (2538, 3124) mmol/L in IF and 3053 (2737, 3292)
in CF group (P ¼ 0.01). The concentrations of Ala, Asn, Asp, His, Ile,
Leu, Met, Orn, Pro, Thr and Val were signiﬁcantly higher in CF in-
fants, while Phe, Tyr and Trp were signiﬁcantly higher in IF infants.
Branched chain AA concentrations of BF infants were more similar
to concentrations in the IF group, while some other AA, including
Phe and Trp tended to be more similar between BF and CF infants.Fig. 3. Anthropometric gain per 100 kcal in intervention and control group. *P < 0.05.
Signiﬁcantly different between groups (Student’s t-test).The total AA concentration of IF was comparable to BF while
essential AA levels, but not Thr, were signiﬁcantly lower in BF than
in IF.
4. Discussion
4.1. Growth, acceptance and tolerance
This randomized, controlled, double-blind intervention study
demonstrated that the growth of infants fed a modiﬁed infant
formula with reduced protein with ALAB and LC-PUFA is similar
and within normal ranges for formula fed infants. The absolute
growth values of the IF (30.2 6.3 g/d) and CF (28.3 6.5 g/d) were
comparable (in PP and ITT population) and similar to those found in
other studies, e.g. 27.8  4.7 g/d23 and 28.1  5.4 g/d.33 In the
BeMIM study, no statistical differences in weight gain were found
between the groups, whereas a tendency towards higher weight
gain was observed in IF infants. Gain in weight and length was
proportional in both study formula groups (IF: R¼ 0.323, P¼ 0.003;
CF: 0.391, P < 0.001). Weight-for-length z-score was higher in IF
infants compared to CF infants at all time points studied (Fig. 1,
supplemental data). This is in contrast to other studies that found
lower weight-for-length z-scores in infants fed a protein reduced
formulae.7,33 To assess the long term growth and anthropometry,
follow-up visits of these children, speciﬁcally at the age of 4 and 6
years are planned.
All infants accepted IF well and for all parameters studied no
negative effects were been found. The signiﬁcantly lower rate in
total adverse events (adverse event plus serious adverse event) in
the IF group compared to the CF group could be related to the ALAB
addition. ALAB was proposed to have immunostimulatory effects
and antibacterial properties and thus be protective against
infections.16
4.2. Nutrition and satiety
The nutritional intake was adequate from study formulae, did
not result in inferior growth and not in compensatory greater
intake of formula, complementary diet or liquids compared to BF
infants. Our ﬁndings in energy and protein intake differed from
Fomon et al. 1999.34 In this study infants of the lower protein group
(1.7 g protein/100 kcal) consumed signiﬁcantly more formula and
thus signiﬁcantly more energy than the infants with the higher
protein formula. In Fomon’s study, this resulted in a higher BMI of
the lower protein group infants suggesting a higher fat
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was observed by Fomon et al. 1999 and it was concluded that the
formula with 1.7 g protein/100 kcal may not be safe.34 In BeMIM
study, no signiﬁcantly higher intake in the IF group was found, thus
the protein content of 1.89 g/100 kcal can be considered adequate
with the protein quality provided. Plasma concentrations of urea
depend on mainly dietary protein intake and indicate the level of
nitrogen excretion if nitrogen intake exceeds the needs for protein
synthesis and growth or dietary proteins are imbalanced.23 Plasma
urea concentrations of IF and CF infants were similar, and bothwere
signiﬁcantly higher than in BF infants which is consistent with a
higher protein intake with both formulae. Different protein intakes
have been related to differences in growth between breastfed and
formula fed infants.35
The energy intake via study formulae was similar to previously
reported intakes of healthy term infants.7,14,36 However, IF infants
had a signiﬁcantly lower energy intake than CF infants at 90 and
120 days of age. While volume intake per meal was not different,
the lower intake in the IF group was explained by a lower meal
frequency, which might indicate a higher satiety. The adequate
protein intake and a balanced AA composition of IF were improved
by substitution of b-lactoglobulin by ALAB (rich in Trp) and addition
of Trp and Phe as free AA. Thereby, a signiﬁcantly higher Trp to large
neutral AA ratio (Trp/large neutral AA) in plasmawas achieved in IF
(median: 0.11; IQR: 0.10; 0.13) compared to CF (0.10:0.09; 0.11,
P < 0.001). While, Trp and large neutral AA compete for transport
proteins in the blood-brain-barrier, a higher Trp/large neutral AA
ratio results in higher Trp levels in the brain.36 Trp as precursor of
the neurotransmitter serotonin inﬂuences the sleep-wake rhythm
and is involved in the appetite regulation.37 According to Halford
et al. 2005 supplementation of serotonin precursors, Trp or 5-
hydroxytryptophan decreases food intake.38 Thus, via an
increased Trp/large neutral AA ratio, IF may have led to higher
satiety and less formula intake in the IF group.
4.3. Energetic efﬁciency
Both formulae appear safe with respect to infant growth. The
apparently minor differences in composition seem to affect ener-
getic efﬁciency for growth. The higher energetic efﬁciency of the
new infant formula (IF), in spite of its lower protein content, could
be due to the improvement of protein composition by the addition
of ALAB. Davis et al. 2008 compared the growth of infants, who
were fed a formula with replacement of 2.2 g/L b-lactoglobulin by
2.2 g/L ALAB to the growth of infants receiving an unmodiﬁed
formula (1.3 g/L ALAB).14 Growth was not statistically different
between groups, but tended to be higher in the ALAB group.
Furthermore, a slightly lower energy intake was observed in the
ALAB-rich formula group. The ALAB-rich formula group had a
0.55 g/100 kcal (calculated from energy intake and weight gain)
higher weight gain than the standard formula group. Davis et al.
2008 observed this difference after 8 weeks of intervention.14 In
BeMIM study a difference of 0.78 g/100 kcal was observed after 12
weeks of intervention.
Several beneﬁcial properties have been ascribed to ALAB in in-
fant formula: ALAB is highly digestible and provides a well-
balanced AA mixture, while positively affecting mineral absorp-
tion, gut microﬂora and immune function.16 Furthermore fat ab-
sorption might inﬂuence energetic efﬁciency of infant formulae.
The fat absorption coefﬁcient in formula fed term infants is about
90%.39 IF had a markedly higher phospholipid content than CF (no
phospholipids) which even exceeded phospholipid content of hu-
man milk fat consisting of >98% triacylglycerols, 0.7% phospho-
lipids and 0.5% cholesterol.40 In BeMIM study, phospholipids from
egg oil were used as main source of arachidonic acid resulting inhigher plasma levels of this fatty acid in the IF group compared to
CF, which did not provide LC-PUFA. The bioavailability of LC-PUFA
depends on the chemical form of fatty acid esters. Amate et al.
investigated the effect of different LC-PUFA sources, triacylglycerols
or phospholipids, on the rate of fat acid absorption in rats.41 Their
results showed, that the fat absorption of some saturated fatty acids
and docosahexaenoic acid from egg-phospholipids were higher
than from triacylglycerols. Sala-Vila et al. (2004),42 argued that the
incorporation of LC-PUFA into plasma phospholipids depends more
on the fatty acid composition of the diet fed than on the source (TG
or PL) of the dietary LC-PUFA. Although, a positive relation between
LC-PUFA, especially arachidonic acid, and growth has been
observed by Carlson et al. (1993),43 we found no correlation be-
tween weight gain and plasma levels of arachidonic acid or doco-
sahexaenoic acid in BeMIM study. This is in line with several other
studies indicating that arachidonic acid and docosahexaenoic acid
supplementation do not signiﬁcantly inﬂuence weight, length or
head circumference gain.6,44,45
Several meta-analyses show the protective effect of breast-
feeding on overweight.46e48 The inverse relationship between
duration of breastfeeding and the risk of overweight has been
related to the protein and caloric intake.46,47 The multicentric Eu-
ropean CHOP study, in 1138 healthy, formula fed infants received a
protein reduced or a higher protein infant and follow-on formula,
has shown that decreasing the protein intake from 11.7 to 7.1% of
energy in the infant formula and from 17.6 to 8.8% in the follow-on
formula was associated with normalization of early weight gain as
compared to breastfed infants.7 A higher protein intake in formula
fed infants results in higher BMI levels than in breastfed infants and
thus may increase the risk for later obesity.7,49 Thereby, the meta-
bolic programming of later obesity risk seems to occur within one
or two years of life.50,51 Thus, a high weight gain during this period
should be avoided.
A limitation of this study is, that more than one components of
the IF have been changed compared to CF. The new modiﬁed for-
mula (IF) according to the European directives of 200628 was
compared to a standard formula (CF) of European directives of
1999.29 Thereby, protein source, macronutrient composition as well
as content of LC-PUFA differed between the formulas. Thus, we can
only assume that ALAB addition and improvement of dietary AA
composition was the major reason for improved energy efﬁciency
of IF.
We conclude that an ALAB containing infant formula with a
protein/energy ratio of 1.89 g/100 kcal and improved LC-PUFA
status provides an adequate intake during the ﬁrst months of life
can be considered safe. This modiﬁed infant formula is appropriate
for term infants as evidenced by growth velocities, acceptance and
tolerance. We consider it most likely that the higher energetic ef-
ﬁciency of the modiﬁed infant formula due to the higher content of
ALAB and Trp. The results obtained in this trial support the general
conclusion that all considerable changes in infant formula
composition should be evaluated by clinical trials inlcuding as-
sessments of infant growth.
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